Oral hypoglycemic therapy in the practice of a general practitioner
- Autores: Demidova T.Y.1
-
Afiliações:
- Russian medical academy of continuing professional education
- Edição: Nº 6 (2016)
- Páginas: 36-42
- Seção: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277734
- ID: 277734
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Review article presents a contemporary view on the application in practice of a general practitioner first-line drugs in the treatment of type 2 diabetes: metformin and a sulfonylurea. Particular attention is paid to the practical application of the latest generation of sulfonamides - glimepiride. Possible combination with other pharmacological agents and antidiabetic drug titration algorithm. Author considers the latest scientific data on the cardiovascular safety of antidiabetic therapy and presents data of new studies that have shown cardioprotective and anti-atherosclerotic properties glimepiride.
Palavras-chave
Texto integral
Sobre autores
Tatiana Demidova
Russian medical academy of continuing professional education
Email: t.y.demidova@gmail.com
MD, professor, professor of the Department of endocrinology
Bibliografia
- Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Выпуск 6. Российская ассоциация эндокринологов. Под ред. И.И. Дедова, М.В. Шестаковой. М.: Информполиграф, 2015. 119 с. [Algorithms of specialized medical care for patients with diabetes. Issue 6. Russian association of endocrinologists. Ed. by I.I. Dedov, M.V. Shestakova. M: Informpoligraf, 2015. 119 p. (in Russian)]
- Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2012;35(6):1364-79.
- Иванов Н.В., Ворохобина Н.В. Практический алгоритм и тактика ведения больных сахарным диабетом 2 типа в амбулаторной практике врача эндокринолога, диабетолога и терапевта. Балтийский журнал современной эндокринологии. 2011;2:91-8. [Ivanov N.V., Vorokhobina N.V. Practical algorithm and tactics of management of patients with diabetes type 2 diabetes in outpatient practice doctor, endocrinologist, diabetologist and physician. Baltic journal of modern endocrinology. 2011;2:91-8 (in Russian)]
- Иванов Н.В. Сульфонилмочевина, открытая вновь. Балтийский форум современной эндокринологии. 2015;11:48-9. [Ivanov N.V. Sulfonylurea, opened again. Baltic forum of modern endocrinology. 2015;11:48-9 (in Russian)]
- Shade D.S., Jovanovic L., Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J. Clin. Pharmacol. 1998;38(7):363-641.
- Guo X.H., Lv X.F., Han P. Efficacy and safety of glimepiride as initial treatment in chinese patients with type 2 diabetes mellitus. Curr. Med. Res. Opin. 2013; 29(3):169-74.
- Charpentier G., Fleury F., Kabir M., Vaur L., Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet. Med. 2001;18(10):828-34.
- Monami M., Luzzi C., Lamanna C., Chiasserini V., Addante F., Desideri C.M., Masotti G., Marchionni N., Mannucci E. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes. Metab. Res. Rev. 2006;22(6):477-82.
- Pantalone K.M., Kattan M.W., Yu C., Wells B.J., Arrigain S., Jain A., Atreja A., Zimmerman R.S. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin:a retrospective analysis. Diabetes. Obes. Metab. 2012;14:803-9.
- Wu G.T., Wang L., Li J., Zhu W.Z. Effects of glibenclamide, glimepiride, and gliclazide on ischemic preconditioning in rat heart. Chin. Med. Sci. J. 2007;22:162-8.
- Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., Kiowski W., Amann F.W., Gruber D., Harris S., Burger W. Sulfonylureas and ischaemic preconditioning; a doubleblind, placebo controlled evaluation of glimepiride and glibenclamide. Eur. Heart. J. 1999;20:439-46.
- Mocanu M.M., Maddock H.L., Baxter G.F., Lawrence C.L., Standen N.B., Yellon D.M. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103:3111-6.
- Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Mattheus M., Devins T., Johansen O.E., Woerle H.J., Broedl U.C., Inzucchi S.E. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015;373:21 1 7-28.
- Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Willi ams B., Bompoint S., de Galan B.E., Joshi R., Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358:2560-72.
- Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., Cavender M.A., Udell J.A., Desai N.R., Mosenzon O., McGuire D.K., Ray K.K., Leiter L.A., Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013;369(14):1317-26.
Arquivos suplementares
